Patient Perspective: Khrystal Davis TX RARE works to improve access and health outcomes for nearly three million Texans living with rare diseases. Khrystal Davis, Founder of...
Howard University’s Dr. Sudha Sharma on the Importance of Addressing Health Inequities IGT is proud to have the National Human Genome Center of Howard University as a member of our Scientific, Academic & Medical Council....
IGT Statement on ICER’s Analysis of the Accelerated Approval Pathway WASHINGTON, DC (April 27, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...
The Importance of National Minority Health Month By IGT Scientific, Academic and Medical Council Chair Donna M. Christensen April is National Minority Health Month, a time to recognize...
NEW IGT Policy Resources Available Gene therapies offer a completely new way of treating a range of serious diseases. But before we can realize their full potential, a...
IGT Recognizes Rare Disease Day This Sunday, February 28th marks the 14th Rare Disease Day. Patients, advocates, providers, and others around the world recognize this...
IGT Comments on CMS Final Rule on Value-based Purchasing Arrangements WASHINGTON, DC (December 23, 2020) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...
Patient Perspective: Erin Frey with CureDuchenne CureDuchenne’s mission is to improve the lives of everyone affected by Duchenne through accelerating research to find the cure, improving...
Patient Perspective: Cure SMA September is Newborn Screening Awareness Month, a dedicated time to educate the public about this critical screening. IGT advocates for...
Dr. Peter Marks Clarifies FDA’s Approach to Gene Therapies After CRL for Hemophilia A Treatment By Jennifer McNary, mother of two sons with Duchenne muscular dystrophy, patient advocate and founder of One Rare. For all the incredible...
